Cipher To Discuss Filing Strategy For CIP-Isotretinoin With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency refuses to file Cipher's 505(b)(2) NDA for the acne drug because it believes the submission is eligible for filing as an ANDA, the company says.
You may also be interested in...
Cipher To Appeal “Approvable” Letter for CIP-Isotretinoin
Toronto firm maintains agency’s request for additional clinical data has already been addressed in existing NDA package.
Cipher To Appeal “Approvable” Letter for CIP-Isotretinoin
Toronto firm maintains agency’s request for additional clinical data has already been addressed in existing NDA package.
Cipher Receives “Approvable” Letter For CIP-Isotretinoin
FDA letter appears to resolve questions about the appropriate pathway for the acne medication.